File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation
  • Basic View
  • Metadata View
  • XML View
TitleA case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation
 
AuthorsLau, GKK
Lie, AKW
Kwong, YL
Lee, CK
Hou, J
Lau, YL
Lim, WL
Liang, R1
 
Issue Date2000
 
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
 
CitationBlood, 2000, v. 96 n. 2, p. 452-458 [How to Cite?]
 
AbstractTo compare the clinical and serological outcomes of patients receiving donors' marrow positive or negative for hepatitis B surface antigen (HBsAg), we studied 18 patients of allogeneic hematopoietic cell transplantation receiving HBsAg-positive marrow (group 1) and 18 receiving HBsAg-negative marrow (group 2). The recipients of the 2 groups were matched for hepatitis B virus (HBV) serology, sex, age, underlying hematological diseases, conditioning regimen, and prophylaxis against graft-versus-host diseases. Eight (44.4%) recipients in group 1 and 2 (11.1%) in group 2 suffered from HBV- related hepatitis posttransplant (P = .03). Furthermore, HBV-related hepatic failure was seen in 6 group 1 patients, but in none of the group 2 patients (P = .007). Five of the 9 (55.5%) HBsAg-negative recipients in group 1 became positive after receiving HBsAg-positive marrow. Serum HBV DNA was positive in all 5 donors of these patients, but in none of the donors of recipients who remained HBsAg negative (P = .008). Group 1 patients developing HBV-related hepatitis posttransplant were more likely to have a donor carrying a precore A 1896 and/or core promoter T 1762/A 1764 HBV variant (62.5% versus 0%, P = .007). This study has demonstrated that a high incidence of HBV-related hepatitis was associated with the use of HBsAg- positive marrow for transplant, and a high viral load in the donor appeared to predispose recipients to the development of HBV-related hepatitis posttransplant. Further clinical trials will be necessary to determine the optimal management approach to this problem, including the use of the antiviral agents in the donors and the recipients. (C) 2000 by The American Society of Hematology.
 
ISSN0006-4971
2012 Impact Factor: 9.06
2012 SCImago Journal Rankings: 4.553
 
ISI Accession Number IDWOS:000088234800011
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLau, GKK
 
dc.contributor.authorLie, AKW
 
dc.contributor.authorKwong, YL
 
dc.contributor.authorLee, CK
 
dc.contributor.authorHou, J
 
dc.contributor.authorLau, YL
 
dc.contributor.authorLim, WL
 
dc.contributor.authorLiang, R
 
dc.date.accessioned2010-09-06T07:27:32Z
 
dc.date.available2010-09-06T07:27:32Z
 
dc.date.issued2000
 
dc.description.abstractTo compare the clinical and serological outcomes of patients receiving donors' marrow positive or negative for hepatitis B surface antigen (HBsAg), we studied 18 patients of allogeneic hematopoietic cell transplantation receiving HBsAg-positive marrow (group 1) and 18 receiving HBsAg-negative marrow (group 2). The recipients of the 2 groups were matched for hepatitis B virus (HBV) serology, sex, age, underlying hematological diseases, conditioning regimen, and prophylaxis against graft-versus-host diseases. Eight (44.4%) recipients in group 1 and 2 (11.1%) in group 2 suffered from HBV- related hepatitis posttransplant (P = .03). Furthermore, HBV-related hepatic failure was seen in 6 group 1 patients, but in none of the group 2 patients (P = .007). Five of the 9 (55.5%) HBsAg-negative recipients in group 1 became positive after receiving HBsAg-positive marrow. Serum HBV DNA was positive in all 5 donors of these patients, but in none of the donors of recipients who remained HBsAg negative (P = .008). Group 1 patients developing HBV-related hepatitis posttransplant were more likely to have a donor carrying a precore A 1896 and/or core promoter T 1762/A 1764 HBV variant (62.5% versus 0%, P = .007). This study has demonstrated that a high incidence of HBV-related hepatitis was associated with the use of HBsAg- positive marrow for transplant, and a high viral load in the donor appeared to predispose recipients to the development of HBV-related hepatitis posttransplant. Further clinical trials will be necessary to determine the optimal management approach to this problem, including the use of the antiviral agents in the donors and the recipients. (C) 2000 by The American Society of Hematology.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationBlood, 2000, v. 96 n. 2, p. 452-458 [How to Cite?]
 
dc.identifier.epage458
 
dc.identifier.hkuros55820
 
dc.identifier.isiWOS:000088234800011
 
dc.identifier.issn0006-4971
2012 Impact Factor: 9.06
2012 SCImago Journal Rankings: 4.553
 
dc.identifier.issue2
 
dc.identifier.openurl
 
dc.identifier.pmid10887105
 
dc.identifier.scopuseid_2-s2.0-0034661838
 
dc.identifier.spage452
 
dc.identifier.urihttp://hdl.handle.net/10722/77032
 
dc.identifier.volume96
 
dc.languageeng
 
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
 
dc.publisher.placeUnited States
 
dc.relation.ispartofBlood
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdolescent
 
dc.subject.meshAdult
 
dc.subject.meshBone Marrow Cells - virology
 
dc.subject.meshCase-Control Studies
 
dc.subject.meshFemale
 
dc.subject.meshHematopoietic Stem Cell Transplantation
 
dc.subject.meshHepatitis B - etiology - mortality
 
dc.subject.meshHepatitis B Antibodies - blood
 
dc.subject.meshHepatitis B Surface Antigens - analysis
 
dc.subject.meshHumans
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshTissue Donors
 
dc.titleA case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Lau, GKK</contributor.author>
<contributor.author>Lie, AKW</contributor.author>
<contributor.author>Kwong, YL</contributor.author>
<contributor.author>Lee, CK</contributor.author>
<contributor.author>Hou, J</contributor.author>
<contributor.author>Lau, YL</contributor.author>
<contributor.author>Lim, WL</contributor.author>
<contributor.author>Liang, R</contributor.author>
<date.accessioned>2010-09-06T07:27:32Z</date.accessioned>
<date.available>2010-09-06T07:27:32Z</date.available>
<date.issued>2000</date.issued>
<identifier.citation>Blood, 2000, v. 96 n. 2, p. 452-458</identifier.citation>
<identifier.issn>0006-4971</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/77032</identifier.uri>
<description.abstract>To compare the clinical and serological outcomes of patients receiving donors&apos; marrow positive or negative for hepatitis B surface antigen (HBsAg), we studied 18 patients of allogeneic hematopoietic cell transplantation receiving HBsAg-positive marrow (group 1) and 18 receiving HBsAg-negative marrow (group 2). The recipients of the 2 groups were matched for hepatitis B virus (HBV) serology, sex, age, underlying hematological diseases, conditioning regimen, and prophylaxis against graft-versus-host diseases. Eight (44.4%) recipients in group 1 and 2 (11.1%) in group 2 suffered from HBV- related hepatitis posttransplant (P = .03). Furthermore, HBV-related hepatic failure was seen in 6 group 1 patients, but in none of the group 2 patients (P = .007). Five of the 9 (55.5%) HBsAg-negative recipients in group 1 became positive after receiving HBsAg-positive marrow. Serum HBV DNA was positive in all 5 donors of these patients, but in none of the donors of recipients who remained HBsAg negative (P = .008). Group 1 patients developing HBV-related hepatitis posttransplant were more likely to have a donor carrying a precore A 1896 and/or core promoter T 1762/A 1764 HBV variant (62.5% versus 0%, P = .007). This study has demonstrated that a high incidence of HBV-related hepatitis was associated with the use of HBsAg- positive marrow for transplant, and a high viral load in the donor appeared to predispose recipients to the development of HBV-related hepatitis posttransplant. Further clinical trials will be necessary to determine the optimal management approach to this problem, including the use of the antiviral agents in the donors and the recipients. (C) 2000 by The American Society of Hematology.</description.abstract>
<language>eng</language>
<publisher>American Society of Hematology. The Journal&apos;s web site is located at http://bloodjournal.hematologylibrary.org/</publisher>
<relation.ispartof>Blood</relation.ispartof>
<subject.mesh>Adolescent</subject.mesh>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Bone Marrow Cells - virology</subject.mesh>
<subject.mesh>Case-Control Studies</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Hematopoietic Stem Cell Transplantation</subject.mesh>
<subject.mesh>Hepatitis B - etiology - mortality</subject.mesh>
<subject.mesh>Hepatitis B Antibodies - blood</subject.mesh>
<subject.mesh>Hepatitis B Surface Antigens - analysis</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Tissue Donors</subject.mesh>
<title>A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0006-4971&amp;volume=96&amp;issue=2&amp;spage=452&amp;epage=458&amp;date=2000&amp;atitle=A+case-controlled+study+on+the+use+of+HBsAg-positive+donors+for+allogeneic+hematopoietic+cell+transplantation</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.pmid>10887105</identifier.pmid>
<identifier.scopus>eid_2-s2.0-0034661838</identifier.scopus>
<identifier.hkuros>55820</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-0034661838&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>96</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>452</identifier.spage>
<identifier.epage>458</identifier.epage>
<identifier.isi>WOS:000088234800011</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong